The Tipógrafo »FSI Approves Cannabis Drug to Mitigate the Effects of Multiple Sclerosis

<! –

->

Multiple sclerosis is a disease that affects the central nervous system. In the world, it affects more than two million people and in our country it is estimated that there are 12 chaos for 10 million inhabitants, with which more than two thousand people, often young women, would suffer from this disease.

Thank you. With the approval of the Institute of Public Health of Chile, the country now has the first cannabis derivative drug for adjuvant treatment of spasticity in patients with moderate to severe multiple sclerosis , which do not respond to antispastic treatments. former.

One of the most common symptoms of this disease is spasticity; a symptom characterized by progressive muscular stiffness, cramps and muscle spasms that produce pain, functional limitation and a significant deterioration in the quality of life of those who suffer from it.

This new cannabis derivative, derived from cannabis, was developed and manufactured by GW Pharmaceuticals in England. , who research and develop scientific evidence on the medical use of cannabinoids for over 20 years.

This drug is different from cannabis for recreational or artisbad use because it is produced according to a patented and standardized process that guarantees the concentrations of the active substances of cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD) are in balanced proportion, in all the batches produced and in each of the sprays, which makes it possible to individualize the appropriate dose to obtain a satisfactory result, avoiding the high concentrations and the risks badociated with cannabinoids, while offering the beneficial effects of the synergy of the combination of those -this.

This medicine has been approved in 30 countries around the world. In Chile, it has been approved as a prescription drug whose prescription has been suspended in patients over 18 years of age and bearing the indication specified in the Health Registry of the Institute of public health (PSI): moderate to severe spasticity in patients with multiple sclerosis. they do not respond to the usual anti-spastic treatment.

This therapeutic innovation will allow these difficult-to-manage patients to have a therapeutic option to improve their symptoms, their functionality and their quality of life, with safety and broad scientific support.